Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Quantifying the effect of metformin treatment and dose on glycemic control.

Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ.

Diabetes Care. 2012 Feb;35(2):446-54. doi: 10.2337/dc11-1465.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.
4.

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.

Phung OJ, Scholle JM, Talwar M, Coleman CI.

JAMA. 2010 Apr 14;303(14):1410-8. doi: 10.1001/jama.2010.405.

PMID:
20388897
5.

Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.

Thomsen RW, Baggesen LM, Søgaard M, Pedersen L, Nørrelund H, Buhl ES, Haase CL, Johnsen SP.

Diabetologia. 2015 Oct;58(10):2247-53. doi: 10.1007/s00125-015-3698-1. Epub 2015 Aug 16.

PMID:
26277380
6.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
8.

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.

Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM.

Curr Med Res Opin. 2009 Mar;25(3):569-83. doi: 10.1185/03007990802705679 .

PMID:
19232032
9.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.

BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.

PMID:
22411919
10.

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

Gross JL, Kramer CK, Leitão CB, Hawkins N, Viana LV, Schaan BD, Pinto LC, Rodrigues TC, Azevedo MJ; Diabetes and Endocrinology Meta-analysis Group (DEMA).

Ann Intern Med. 2011 May 17;154(10):672-9. doi: 10.7326/0003-4819-154-10-201105170-00007. Review.

PMID:
21576535
11.

Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.

Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT.

Drugs Aging. 2004;21(4):259-71.

PMID:
15012171
12.

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.

Bays HE, Goldberg RB, Truitt KE, Jones MR.

Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.

PMID:
18852398
14.

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.

Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group.

Diabetes Obes Metab. 2008 Sep;10(10):959-69. doi: 10.1111/j.1463-1326.2007.00839.x. Epub 2008 Jan 14.

PMID:
18201203
15.

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.

Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M.

Curr Med Res Opin. 2008 Feb;24(2):537-50. doi: 10.1185/030079908X260925 .

PMID:
18194595
16.

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

Bosi E, Dotta F, Jia Y, Goodman M.

Diabetes Obes Metab. 2009 May;11(5):506-15. doi: 10.1111/j.1463-1326.2009.01040.x. Epub 2009 Mar 23.

PMID:
19320662
17.

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.

Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ.

Curr Med Res Opin. 2011 Jan;27(1):189-95. doi: 10.1185/03007995.2010.536755. Epub 2010 Dec 9.

PMID:
21142610
19.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
20.

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE.

J Clin Endocrinol Metab. 2012 May;97(5):1615-22. doi: 10.1210/jc.2011-2243. Epub 2012 Mar 14.

PMID:
22419732

Supplemental Content

Support Center